Equities analysts predict that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will announce earnings of ($1.67) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.38) and the lowest is ($1.83). Esperion Therapeutics posted earnings of ($0.62) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 169.4%. The firm is expected to report its next quarterly earnings results after the market closes on Tuesday, August 8th.

According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($6.80) per share for the current financial year, with EPS estimates ranging from ($7.40) to ($6.00). For the next year, analysts anticipate that the business will post earnings of ($5.38) per share, with EPS estimates ranging from ($6.43) to ($4.38). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by $0.30. During the same quarter in the previous year, the firm earned ($0.62) EPS.

Several research firms have recently issued reports on ESPR. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Needham & Company LLC upped their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a report on Tuesday. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. UBS AG restated a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Finally, Stifel Nicolaus restated a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $39.16.

A number of large investors have recently modified their holdings of the stock. Teachers Advisors LLC raised its stake in shares of Esperion Therapeutics by 56.7% in the fourth quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 12,122 shares in the last quarter. Bank of Montreal Can raised its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock valued at $1,387,000 after buying an additional 921 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Esperion Therapeutics during the first quarter valued at approximately $961,000. Finally, Wells Fargo & Company MN raised its stake in Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,282 shares in the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Shares of Esperion Therapeutics (NASDAQ ESPR) traded up 15.41% during mid-day trading on Tuesday, hitting $52.13. 4,151,267 shares of the stock were exchanged. The stock’s 50 day moving average is $45.38 and its 200-day moving average is $33.91. The stock’s market cap is $1.18 billion. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38.

TRADEMARK VIOLATION WARNING: This article was published by American Banking News and is owned by of American Banking News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/08/08/esperion-therapeutics-inc-espr-expected-to-announce-earnings-of-1-67-per-share.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Get a free copy of the Zacks research report on Esperion Therapeutics (ESPR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.